Onyx Pharmaceuticals Inc. is no longer an independently traded public company, meaning it does not possess a live active stock price. The enterprise was officially acquired by Amgen Inc. in a multi-billion-dollar all-cash transaction at $125 per share, following which its common stock ticker symbol was permanently delisted from the Nasdaq stock exchange.